Pratt Collard Advisory Partners LLC trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 8.3% during the 1st quarter, Holdings Channel reports. The institutional investor owned 8,945 shares of the company’s stock after selling 805 shares during the quarter. Pratt Collard Advisory Partners LLC’s holdings in Eli Lilly And Co were worth $1,161,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Athena Capital Advisors LLC bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at approximately $26,000. Wakefield Asset Management LLLP bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at approximately $27,000. Larson Financial Group LLC bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at approximately $29,000. Ironwood Financial llc bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at approximately $30,000. Finally, Trust Department MB Financial Bank N A grew its stake in shares of Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares during the last quarter. 79.58% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE LLY opened at $115.20 on Friday. Eli Lilly And Co has a fifty-two week low of $77.09 and a fifty-two week high of $132.13. The company has a market capitalization of $128.52 billion, a P/E ratio of 20.76, a price-to-earnings-growth ratio of 2.35 and a beta of 0.33. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. During the same quarter in the prior year, the company earned $1.14 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. Research analysts predict that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Bank of America set a $129.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research note on Thursday, March 21st. Credit Suisse Group set a $121.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research note on Friday, March 22nd. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price target on the stock in a research note on Wednesday, April 10th. Guggenheim cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price target on the stock. in a research note on Thursday, April 11th. Finally, UBS Group assumed coverage on shares of Eli Lilly And Co in a research note on Wednesday, March 20th. They set a “buy” rating and a $74.51 price target on the stock. Ten investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has a consensus rating of “Buy” and an average target price of $118.02.
In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 10,000 shares of the stock in a transaction on Friday, April 12th. The stock was sold at an average price of $124.65, for a total transaction of $1,246,500.00. Following the completion of the sale, the senior vice president now owns 57,806 shares in the company, valued at $7,205,517.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 867,382 shares of company stock worth $109,265,182. Company insiders own 0.11% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Eli Lilly And Co (LLY) Shares Sold by Pratt Collard Advisory Partners LLC” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2019/04/19/eli-lilly-and-co-lly-shares-sold-by-pratt-collard-advisory-partners-llc.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.